What should I do about worsening insomnia after tapering amitriptyline from 10 mg to 7.5 mg, given that increasing back to 10 mg made me feel worse?

Management of Amitriptyline Withdrawal-Related Insomnia

You should discontinue amitriptyline completely and initiate cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, as your insomnia appears to be medication-induced rather than a primary sleep disorder that requires continued pharmacotherapy. 1

Understanding Your Situation

Your clinical presentation is consistent with amitriptyline withdrawal-induced sleep disturbance, not primary insomnia disorder requiring continued treatment. Several key factors support this:

• You did not have insomnia prior to starting amitriptyline 2
• The insomnia emerged specifically during dose reduction (from 10mg to 7.5mg) 2
• Increasing back to 10mg worsened your symptoms rather than improving them, which is atypical for dose-responsive insomnia treatment 2
• The timeline (4 months and worsening) suggests a protracted withdrawal phenomenon rather than undertreated insomnia 2

Research demonstrates that 8 of 10 patients who discontinued long-term amitriptyline (average dose 138mg) developed depression within 3-15 weeks, and some experienced a mild withdrawal syndrome consisting of irritability, dream and sleep disturbance, and restlessness during the first few weeks after discontinuation. 2

Recommended Treatment Approach

Primary Intervention: CBT-I

Cognitive behavioral therapy for insomnia should be your initial treatment, as it is the first-line recommendation for chronic insomnia disorder in adults. 1 This is a strong recommendation based on moderate-quality evidence from the American College of Physicians. 1

CBT-I consists of:

• Cognitive therapy targeting sleep-related thoughts and beliefs 1
• Behavioral interventions including sleep restriction and stimulus control 1
• Sleep hygiene education 1
• Available formats include in-person (individual or group), telephone-based, web-based modules, or self-help books 1

Why Not Continue or Adjust Amitriptyline

Amitriptyline is not FDA-approved for insomnia treatment and should not be used as a long-term solution for your situation. 3, 4 Several critical points:

• The FDA label indicates amitriptyline is approved for depression, not insomnia 3
• A 2025 randomized controlled trial found that low-dose amitriptyline (10-20mg) produced only a statistically significant but not clinically relevant reduction in insomnia severity at 6 weeks, with no benefit at later timepoints 5
• The same trial showed amitriptyline did not achieve clinically meaningful improvement or recovery rates compared to placebo 5
• Evidence quality for antidepressants in insomnia is low, with uncertain tolerability and safety due to limited adverse event reporting 4
• The 2023 European Insomnia Guideline specifically recommends against using low-dose sedating antidepressants for long-term treatment 6

Discontinuation Strategy

Complete discontinuation of amitriptyline is appropriate given your clinical picture. 2 Since you're already at 7.5mg and have been at this dose for 4 months:

• You may experience transient worsening of sleep disturbance, irritability, and restlessness during the first 2 weeks after complete discontinuation 2
• These withdrawal symptoms are typically mild and self-limited 2
• The fact that increasing back to 10mg made you feel worse suggests you may be experiencing paradoxical effects or sensitization, making continued use counterproductive 7

If CBT-I Alone Is Insufficient

Only after CBT-I has been tried and found insufficient should pharmacological therapy be considered through shared decision-making. 1 This is a weak recommendation based on low-quality evidence. 1

If medication becomes necessary:

• Orexin receptor antagonists (like daridorexant) can be used for up to 3 months or longer in some cases 6
• Benzodiazepine receptor agonists may be used short-term (≤4 weeks), though longer-term use carries risks of dependence, tolerance, dementia, fractures, and major injuries 8, 6
• These should only be considered after documented CBT-I failure, not as a substitute for proper behavioral treatment 1

Critical Pitfalls to Avoid

• Do not attempt further dose adjustments of amitriptyline - your response pattern (worsening with re-escalation) indicates this is not the appropriate medication for you 2, 7
• Do not interpret your current insomnia as requiring continued antidepressant treatment - this appears to be withdrawal-related, not primary insomnia 2
• Do not skip CBT-I in favor of medication - guidelines strongly recommend CBT-I first, and evidence shows medications often fail to produce remission even when they show statistical benefit 8, 1
• Avoid the common GP practice of prescribing amitriptyline off-label for insomnia - while 95% of surveyed GPs report prescribing it and 31% do so commonly, this practice lacks evidence support and is driven more by perceived patient pressure than clinical effectiveness 9